Bimekizumab for the treatment of Psoriatic Arthritis (PsA): a cost-per-responder (CPR) analysis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2286; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Across evaluated countries, the CPR for bimekizumab was 44%-61% of the CPR for risankizumab. These findings highlight the potential for improved economic efficiency alongside clinical efficacy with bimekizumab in the management of active PsA. The consistent cost-per-responder advantage observed across countries and outcomes supports the value of bimekizumab as a treatment option in diverse healthcare settings, and may help inform clinical and economic decision-making in adults with active PsA."
Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
|
|
Kevin Lock 1; Flore Decuypere 2; Remi Marty 2; Derek Ems 3; Eiko Yamamura 4; Hwabok Yi 5; Robert Lo 6; Stephanie Stypa 7; Carla de Agostino Biella 8; Omar Perez Enriquez 9; Paloma Charlesworth 10; and Oliver Burn 10
|